Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Antonio Di Stefano, Antonio Iannitelli, Sara Laserra & Piera Sozio. (2011) Drug delivery strategies for Alzheimer's disease treatment. Expert Opinion on Drug Delivery 8:5, pages 581-603.
Read now
Read now
Articles from other publishers (35)
Gayatri Devi. (2023) A how-to guide for a precision medicine approach to the diagnosis and treatment of Alzheimer's disease. Frontiers in Aging Neuroscience 15.
Crossref
Crossref
Uzma Saleem, Zunera Chauhdary, Sumera Islam, Aimen Zafar, Rana O. Khayat, Norah A. Althobaiti, Ghulam Mujtaba Shah, Mohammed Alqarni & Muhammad Ajmal Shah. (2022) Sarcococca saligna ameliorated D-galactose induced neurodegeneration through repression of neurodegenerative and oxidative stress biomarkers. Metabolic Brain Disease 38:2, pages 717-734.
Crossref
Crossref
Mehmet Ilkin Naharci, Betul Gulsum Yavuz Veizi, Bilal Katipoglu, Ece Akcan, Fatma Yoruk & Ilker Tasci. (2022) Massive Weight Loss From Rivastigmine Patch in an Older Patient. Journal of Clinical Psychopharmacology 42:2, pages 222-224.
Crossref
Crossref
Xiaodi Kou, Juanjuan Liu, Yuhong Chen, Aihong Yang & Rui Shen. (2021) Emodin derivatives with multi-factor anti-AD activities: AChE inhibitor, anti-oxidant and metal chelator. Journal of Molecular Structure 1239, pages 130459.
Crossref
Crossref
Michael Camilleri. (2021) Gastrointestinal motility disorders in neurologic disease. Journal of Clinical Investigation 131:4.
Crossref
Crossref
Kevin Nguyen, Heidi Hoffman, Binu Chakkamparambil & George T Grossberg. (2021) Evaluation of rivastigmine in Alzheimer's disease. Neurodegenerative Disease Management 11:1, pages 35-48.
Crossref
Crossref
Ahmet T. Isik, Esra Ates Bulut, Ozge Dokuzlar, Derya Kaya, Neziha Erken, Fatma S. Dost Gunay & Mehmet S. Ontan. (2020) Cardiac and Blood Pressure Safety of Transdermal Rivastigmine in Elderly Patients With Dementia With Lewy Bodies. Alzheimer Disease & Associated Disorders 34:4, pages 339-343.
Crossref
Crossref
Norwin Kubick, Patrick C. Henckell Flournoy, Ana-Maria Enciu, Gina Manda & Michel-Edwar Mickael. (2020) Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer’s Disease. Pharmaceutics 12:9, pages 880.
Crossref
Crossref
Mayank Singhal, Virginia Merino, Michela Rosini, Andrea Cavalli & Yogeshvar N. Kalia. (2019)
Controlled Iontophoretic Delivery
in Vitro
and
in Vivo
of ARN14140—A Multitarget Compound for Alzheimer’s Disease
. Molecular Pharmaceutics 16:8, pages 3460-3468.
Crossref
Crossref
Cornelis J. Van der Schyf. (2016) Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases. Drug Development Research 77:8, pages 458-468.
Crossref
Crossref
G. Villanueva, M. López de Argumedo & I. Elizondo. (2016) Dementia drug consumption in the Basque Country between 2006 and 2011. Neurología (English Edition) 31:9, pages 613-619.
Crossref
Crossref
G. Villanueva, M. L?pez de Argumedo & I. Elizondo. (2016) Consumo de medicamentos para el tratamiento de la demencia en la Comunidad Aut?noma Vasca durante el periodo 2006-2011. Neurolog?a 31:9, pages 613-619.
Crossref
Crossref
. 2016. Drug Delivery. Drug Delivery
481
522
.
Eman Bahrani, Chloe E. Nunneley, Sylvia Hsu & Joseph S. Kass. (2016) Cutaneous Adverse Effects of Neurologic Medications. CNS Drugs 30:3, pages 245-267.
Crossref
Crossref
Adrian Imbern?n-Moya, Sebastian Podlipnik, Fernando Burgos, Elena Vargas-Laguna, Antonio Aguilar-Mart?nez, Eva Fern?ndez-Cogolludo & Miguel Angel Gallego-Valdes. (2016) Acquired Localized Hypertrichosis Induced by Rivastigmine. Case Reports in Dermatological Medicine 2016, pages 1-3.
Crossref
Crossref
Yu Nakamura, Christine Strohmaier, Kaoru Tamura, Naoko Kataoka, Masayuki Nakano, Shoichiro Oda, Kazuma Nishimura & Akira Homma. (2015) A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra 5:3, pages 361-374.
Crossref
Crossref
Audrey Fischer, Marc Wolman, Michael Granato, Michael Parsons, Andrew S. McCallion, Jody Proescher & Emily English. (2015) Carbamate nerve agent prophylatics exhibit distinct toxicological effects in the zebrafish embryo model. Neurotoxicology and Teratology 50, pages 1-10.
Crossref
Crossref
Alanna Dancis & Valerie T. Cotter. (2015) Diagnosis and Management of Cognitive Impairment in Parkinson?s Disease. The Journal for Nurse Practitioners 11:3, pages 307-313.
Crossref
Crossref
Hae Ri NaMoon Ho ParkSangYun KimDong Won YangSeong-Hye ChoiHyun Duk YangYoungSoon YangHyun Jeong HanJung Seok LeeYoung-Chul YoonSeong-Ho KohJung Eun KimBon D. KuHee-Jin KimKyung Won ParkEun-Joo KimBora YoonKey Jung Park. (2015) Factors Influencing Skin Tolerability to the Rivastigmine Patch in Patients with Alzheimer's Disease. Dementia and Neurocognitive Disorders 14:1, pages 31.
Crossref
Crossref
Matthias Riepe, John Weinman, Judith Osae-Larbi, Amy Mulick Cassidy, Sean Knox, Ricardo Chaves & Beate Müller. (2015) Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers. Dementia and Geriatric Cognitive Disorders 40:1-2, pages 107-119.
Crossref
Crossref
Nienke M. S. Gol?ke, Astrid M. van Strien, Paul J. L. Dautzenberg, Naomi Jessurun & Carolina J. P. W. Keijsers. (2014) Skin Lesions after Oral Acetylcholinesterase Inhibitor Therapy: A Case Report. Journal of the American Geriatrics Society 62:10, pages 2012-2013.
Crossref
Crossref
Patrick P. Basu, Niraj James Shah, Mark M. Aloysius & Robert S. Brown. (2014) Randomized, Placebo-Controlled Trial of Transdermal Rivastigmine for the Treatment of Encephalopathy in Liver Cirrhosis (TREC Trial). Open Journal of Gastroenterology 04:06, pages 255-264.
Crossref
Crossref
A.J. Cruz Jentoft & B. Hernández. (2014) Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study. Neurología (English Edition) 29:1, pages 1-10.
Crossref
Crossref
A.J. Cruz Jentoft & B. Hernández. (2014) Manejo terapéutico con rivastigmina en pacientes con enfermedad de Alzheimer de leve a moderadamente grave en condiciones de práctica clínica habitual. Estudio ENTERPRISE. Neurología 29:1, pages 1-10.
Crossref
Crossref
Michael Camilleri & Adil E. Bharucha. 2014. Aminoff's Neurology and General Medicine. Aminoff's Neurology and General Medicine
255
271
.
Kongkiat KULKANTRAKORN, Panas TANYAKITPISAL, Somchai TOWANABUT, Charungthai DEJTHEVAPORN, Poonsri RANGSEEKAJEE, Sunsanee PONGPAKDEE, Somsak LAPTIKULTHAM, Kritsada RODPRASERT, Suwanna SETTHAWATCHARAWANICH & Bandit THINKHAMROP. (2012) Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand. Psychogeriatrics 13:1, pages 1-8.
Crossref
Crossref
V. P. Prasher, N. Sachdeva, C. Adams & M. S. Haque. (2013) Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome‐pilot study. International Journal of Geriatric Psychiatry 28:2, pages 219-220.
Crossref
Crossref
Oscar Bernal-Pacheco, Natlada Limotai, Criscely L. Go & Hubert H. Fernandez. (2012) Nonmotor Manifestations in Parkinson Disease. The Neurologist 18:1, pages 1-16.
Crossref
Crossref
Andrew E. Budson. 2011. The Handbook of Alzheimer's Disease and Other Dementias. The Handbook of Alzheimer's Disease and Other Dementias
313
335
.
Sohita Dhillon. (2011) Rivastigmine Transdermal Patch. Drugs 71:9, pages 1209-1231.
Crossref
Crossref
R. Blesa González, M. Boada Rovira, C. Martínez Parra, D. Gil-Saladié, C.A. Almagro & A.L. Gobartt Vázquez. (2011) Evaluación de la conveniencia del cambio de vía de administración de rivastigmina en pacientes con enfermedad de Alzheimer. Neurología 26:5, pages 262-271.
Crossref
Crossref
Michael J. Aminoff, Chad W. Christine, Joseph H. Friedman, Kelvin L. Chou, Kelly E. Lyons, Rajesh Pahwa, Bastian R. Bloem, Sotirios A. Parashos, Catherine C. Price, Irene A. Malaty, Robert Iansek, Ivan Bodis-Wollner, Oksana Suchowersky, Wolfgang H. Oertel, Jorge Zamudio, Joyce Oberdorf, Peter Schmidt & Michael S. Okun. (2011) Management of the hospitalized patient with Parkinson’s disease: Current state of the field and need for guidelines. Parkinsonism & Related Disorders 17:3, pages 139-145.
Crossref
Crossref
Rüdiger Hardeland. (2011) Cognitive Enhancers in Moderate to Severe Alzheimer's Disease. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6344.
Crossref
Crossref
R. Blesa González, M. Boada Rovira, C. Martínez Parra, D. Gil-Saladié, C.A. Almagro & A.L. Gobartt Vázquez. (2011) Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Neurología (English Edition) 26:5, pages 262-271.
Crossref
Crossref
Maarten MJ van Eijk, Kit CB Roes, Marina LH Honing, Michael A Kuiper, Attila Karakus, Mathieu van der Jagt, Peter E Spronk, Willem A van Gool, Roos C van der Mast, Jozef Kesecioglu & Arjen JC Slooter. (2010) Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. The Lancet 376:9755, pages 1829-1837.
Crossref
Crossref